Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 29CNS 23Breast 22Gastrointestinal 21Lymphoid 12Head & Neck 9Thoracic 6Gynecologic 6Other hematologic neoplasm 5Sarcoma 3Tumor-Agnostic 2Plasma cell 2Other solid neoplasm 2Endocrine 2Dermatologic 2Myeloid 1

Conditions

Carcinoma, Neuroendocrine 2

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Magnetic Resonance Imaging × Endocrine × Clear all
NCT07458906 2026-03-09

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

The First Affiliated Hospital of Xiamen University

Phase NA Recruiting
60 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT01879657 2025-08-06

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Radio Isotope Therapy of America

Phase NA Completed
169 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡